Where does Impel Neuropharma, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Impel Neuropharma, Inc. ranks #26,532 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Impel Neuropharma, Inc. hold?

Impel Neuropharma, Inc. holds 10 US utility patents granted between 2017 and 2022, spanning 4 technology areas.

What is Impel Neuropharma, Inc.'s Innovation Score?

Impel Neuropharma, Inc. has an Innovation Score of 30.3 out of 100 (34th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Impel Neuropharma, Inc.'s patent grant rate increasing or decreasing?

Impel Neuropharma, Inc.'s recent grant velocity is +133% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Impel Neuropharma, Inc.'s patents?

Impel Neuropharma, Inc.'s patents average 21.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Impel Neuropharma, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Impel Neuropharma, Inc.

Q: What technology areas does Impel Neuropharma, Inc. focus on?

Impel Neuropharma, Inc.'s top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 10 patents, ranking #701 of 3,490 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 10 granted patents across 4 technology areas, recorded in grant years 2017–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Impel ranks #26,532 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 4 technology areas.

#26,532
of 49,997 US assignees by volume: 34th percentile
by Innovation Score (30.3/100): 21.2
avg claims per patent: +133%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R26532 · US Corporation #26,532 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #26,532/49,997
PHOTO-FINISH Identy
CPC-NARROW A61M · 4 areas
INNOV-THIN 30.3/100
CLAIMS-DENSE 21.2 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +133% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Identy Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Impel’s 30.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (27%) Velocity 2.2 pts (7%) Breadth 7.1 pts (23%) Claim depth 12.7 pts (42%)

Qualcomm Incorporated · highest

85
Impel Neuropharma · this assignee

30
3D Lighting… · lowest

7

What this shows Impel's Innovation Score is 30.3/100 (34th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Impel?

Each dot is one of Impel’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Impel’s own 21.2 claims/patent is ABOVE the 18.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Impel vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Impel's grants concentrate

Impel Neuropharma, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2021 (4 grants) versus a trough of 1 in 2017. By volume, Impel sits between Identy Inc. and Incoe Corporation.

Impel's three-year grant acceleration

Impel Neuropharma, Inc. shows 2 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Identy

10
Illumigyn

10
Imaginab

10
Immersive Robotic…

10
Impel Pharmaceuti…

10
Inca Digital Prin…

10
Incisive Surgical

10
Incoe

10
Impel Neuropharma ◀

10

What this shows Impel holds 10 patents at rank #26,573, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Impel

By rank, the assignees closest to #26,573 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Impel's primary technology class.

Impel's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 34th percentile higher than 34% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Impel Neuropharma, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	10.0%
2018	1	10.0%
2019	1	10.0%
2020	1	10.0%
2021	4	40.0%
2022	2	20.0%

Which technologies does Impel Neuropharma, Inc. patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 10

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

B05B - Spraying APPARATUS; Atomising APPARATUS; Nozzles 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 2

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Impel Neuropharma, Inc.'s patent record in context - here's where to go next.

Impel Neuropharma, Inc.'s lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 100% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #26,532 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Impel Neuropharma, Inc. against Identy Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.